SEC Comment Letter for Hoth Therapeutics, Inc. (HOTH) (CIK 0001711786) (RKTO) — Apr 10, 2020
Hoth Therapeutics, Inc. (HOTH) (CIK 0001711786)
Date: April 10, 2020 · CIK: 0001711786 · Accession: 0000000000-20-003134
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-237567
Letter
April 10, 2020 Robb Knie Chief Executive Officer Hoth Therapeutics, Inc. 1 Rockefeller Plaza, Suite 1039 New York, NY 10020 Re:Hoth Therapeutics, Inc. Registration Statement on Form S-1 Filed April 3, 2020 File No. 333-237567 Dear Mr. Knie: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact William Mastrianna, Attorney-Adviser, at (202) 551-3778 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Nazia Khan
Show Raw Text
April 10, 2020
Robb Knie
Chief Executive Officer
Hoth Therapeutics, Inc.
1 Rockefeller Plaza, Suite 1039
New York, NY 10020
Re:Hoth Therapeutics, Inc.
Registration Statement on Form S-1
Filed April 3, 2020
File No. 333-237567
Dear Mr. Knie:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact William Mastrianna, Attorney-Adviser, at (202) 551-3778 with any
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Nazia Khan